Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccine.
A 13-year-old girl developed immune thrombocytopenic purpura (ITP) and concomitant positive antiphospholipid antibodies (aPL) following vaccination with a quadrivalent human papillomavirus (HPV) vaccine. During the course of a disease, she developed clinical manifestation with bleeding and she was treated with intravenous immunoglobulins. Consequently, the number of her platelets remained critically low and she was put on corticosteroids and rituximab. Since then, her platelet count remain within the normal range, but her aPL are still present.
The Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Mojca
M
Bizjak
The Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Or
O
Bruck
Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Italy.
Darja
D
Kanduc
Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia.
Sonja
S
Praprotnik
The Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel-Hashomer, Israel; Incumbent of the Laura Schwarz-kipp chair for research of autoimmune diseases, Sackler Faculty of Medicine, Tel-Aviv University, Israel. Electronic address: shoenfel@post.tau.ac.il.
Yehuda
Y
Shoenfeld
D000293:Adolescent; D017152:Antibodies, Antiphospholipid / Q000276:immunology*; D005260:Female; D006801:Humans; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy / Q000276:immunology*
D017152:Antibodies, Antiphospholipid; D053918:Papillomavirus Vaccines
ASIA syndrome; Antiphospholipid antibodies; Human papillomavirus; Immune thrombocytopenic purpura; Molecular mimicry; Vaccine